Parkinson's Disease Clinical Trial
Official title:
Characterizing the Specificity and Stability of Local Field Potentials in the Globus Pallidus Internus of Patients Undergoing Deep Brain Stimulation for Parkinson's Disease
Deep brain stimulation for Parkinson's disease is a well established therapy. Current practice requires tedious adjustment of stimulation settings based on frequent patient assessments. Ultimately, the goal is to develop a system that can program itself using signals that are recorded directly from the brain on a continuous basis. Our previous work has identified abnormal electrical signals in the brain that are targeted for stimulation that can potentially be used to develop a self-programming system. In this study, the investigators will test the safety and utility of a novel adapted device that can not only deliver stimulation to the brain but also record brain signals in a patient that is implanted with a deep brain stimulation system. The purpose of this Phase I study is to understand the safety of the device as well as the relationship between these electrical signals measured from deep within the brain and Parkinson's symptoms and how these signals can be used to guide a self-programmed system. The study will entail implanting this special device (Activa PC+S) in place of the standard generator (Activa PC) and to compare clinical symptoms, recorded brain signals, and stimulation patterns during a one year period after implantation. Specifically, the investigators will use the Activa PC+S to record GPi (internal globus pallidus) local field potentials between and during programming visits, allowing the surgeon to better characterize a patient's disease. At the same time, the investigators will evaluate the safety of this new device.
The device being tested is the Activa Primary Cell and Sensing (PC+S) system which consists
of a deep brain stimulation (DBS) generator, specially adapted extension leads, and DBS
leads implanted in the globus pallidus internus (GPi) in patients with Parkinson's disease
(PD). The Activa PC+S system differs from currently FDA-approved devices in that it is not
only capable of delivering therapeutic stimulation through the DBS leads but also recording
electrophysiological signals through the same leads. The goal of this pilot study is to
evaluate (1) to assess the specificity and stability of the electrophysiological signals
recorded with the Activa PC+S system, (2) how the signals recorded by this system correlate
with clinical parameters and non-invasive measures of movement, and (3) and the safety of
the PC+S system.
The Medtronic Activa Primary Cell (PC) DBS system has a proven record of safety and
reliability through extensive human clinical use over the years1. The potential risks
associated with the placement and the use of the device have been thoroughly described in
previous human trials and retrospective reports. The PC+S device is based on the currently
approved device but with added sensing capabilities. In this protocol, we will evaluate the
Activa PC+S system using additional sensing components with stimulation parameters commonly
used for the treatment of movement disorder.
This trial will follow a non-randomized design with rigorous and comprehensive follow-ups,
as described below.
The study will be conducted at the Ronald Reagan UCLA Medical Center and associated
facilities through the combined neurology and neurosurgery movement disorders program, which
manages over 1,000 patients with PD. The study will provide close follow-up of patients
after DBS surgery by a team involving functional neurosurgeons and neurologists with
expertise in clinical care of patients with PD.
Patients will be screened according to the inclusion/exclusion criteria. Each patient will
be informed about the study to see if they are interested in participating. After the
patient signs the informed consent, they will undergo baseline evaluations, and if they
qualify, they will undergo surgery to implant the deep brain stimulation system.
After device implantation, patients will complete comprehensive follow-up as described in
the protocol below. The patients will return to the clinic at least monthly for the first 3
months for on and off medication assessments and programming. Primary assessments will be
administered monthly for the first 3 months, and then every 3 months up to 12 months
post-operatively.
LFPs will be recorded across time (intraoperative, during programming, and chronically),
across activity states (with quantitative accelerometer and gyroscope measurements), and
across disease states (off and on medication, off and on stimulation) to address the primary
research questions proposed.
A comparison of measures within the same person from pre-treatment to post-treatment will be
performed. Also, pre-treatment and post-treatment group means and standard deviations will
be determined. Correlations between LFP biosignals and non-invasive measures and clinical
assessment of movement will be performed. In addition, correlation between LFP signals and
clinically-defined stimulation parameters will be evaluated.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02915848 -
Long-term Stability of LFP Recorded From the STN and the Effects of DBS
|
||
Recruiting |
NCT03648905 -
Clinical Laboratory Evaluation of Chronic Autonomic Failure
|
||
Terminated |
NCT02688465 -
Effect of an Apomorphine Pump on the Quality of Sleep in Parkinson's Disease Patients (POMPRENELLE).
|
Phase 4 | |
Completed |
NCT05040048 -
Taxonomy of Neurodegenerative Diseases : Observational Study in Alzheimer's Disease and Parkinson's Disease
|
||
Active, not recruiting |
NCT04006210 -
Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations
|
Phase 3 | |
Completed |
NCT02562768 -
A Study of LY3154207 in Healthy Participants and Participants With Parkinson's Disease
|
Phase 1 | |
Completed |
NCT00105508 -
Sarizotan HC1 in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia
|
Phase 3 | |
Completed |
NCT00105521 -
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
|
Phase 3 | |
Recruiting |
NCT06002581 -
Repetitive Transcranial Magnetic Stimulation(rTMS) Regulating Slow-wave to Delay the Progression of Parkinson's Disease
|
N/A | |
Completed |
NCT02236260 -
Evaluation of the Benefit Provided by Acupuncture During a Surgery of Deep Brain Stimulation
|
N/A | |
Completed |
NCT00529724 -
Body Weight Gain, Parkinson, Subthalamic Stimulation
|
Phase 2 | |
Recruiting |
NCT05699460 -
Pre-Gene Therapy Study in Parkinson's Disease and Multiple System Atrophy
|
||
Completed |
NCT03703570 -
A Study of KW-6356 in Patients With Parkinson's Disease on Treatment With Levodopa-containing Preparations
|
Phase 2 | |
Completed |
NCT03462680 -
GPR109A and Parkinson's Disease: Role of Niacin in Outcome Measures
|
N/A | |
Completed |
NCT02837172 -
Diagnosis of PD and PD Progression Using DWI
|
||
Not yet recruiting |
NCT04046276 -
Intensity of Aerobic Training and Neuroprotection in Parkinson's Disease
|
N/A | |
Recruiting |
NCT02952391 -
Assessing Cholinergic Innervation in Parkinson's Disease Using the PET Imaging Marker [18F]Fluoroethoxybenzovesamicol
|
N/A | |
Active, not recruiting |
NCT02937324 -
The CloudUPDRS Smartphone Software in Parkinson's Study.
|
N/A | |
Terminated |
NCT02894567 -
Evaluation of Directional Recording and Stimulation Using spiderSTN
|
N/A | |
Completed |
NCT02874274 -
Vaccination Uptake (VAX) in PD
|
N/A |